Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 15/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9423908 | 0.83 | LMNA (0.55) | DHPSLMNAALDH1A1L3MBTL1MAPT | |
| SCHEMBL29770374 | 0.79 | DHPS (0.58) | DHPS | |
| SCHEMBL618135 | 0.79 | DHPS (0.58) | DHPS | |
| SCHEMBL7700308 | 0.77 | DHPS (0.51) | DHPSLMNAALDH1A1L3MBTL1MAPT | |
| SCHEMBL7303389 | 0.77 | DHPS (0.81) | DHPSLMNAALDH1A1HTTMAPT | |
| SCHEMBL4071996 | 0.76 | DHPS (0.67) | DHPSGAA | |
| SCHEMBL7204802 | 0.76 | DHPS (0.57) | DHPSALDH1A1MAPK1L3MBTL1HTT | |
| SCHEMBL5632471 | 0.76 | DHPS (0.57) | DHPSALDH1A1MAPK1L3MBTL1HTT | |
| SCHEMBL7294963 | 0.76 | DHPS (0.62) | DHPSALDH1A1MAPTMEN1GAA | |
| SCHEMBL6579232 | 0.75 | EDNRA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1191026-B1 | New pyridazine endothelin antagonists | PFIZER LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-6670362-B2 | Treatment of restenosis, acute or chronic renal failure, pulmonary hypertension, systemic hypertension, benign prostatic hyperplasia, male erectile dysfunction, prostate cancer, metastatic bone cancer, angina, atherosclerosis | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-20020061889-A1 | New pyridazine endothelin antagonists | PFIZER INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1191026-A1 | New pyridazine endothelin antagonists | Pfizer Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061889-A1 | New pyridazine endothelin antagonists | EDNRB, EDNRA, ECE1 | DHPS 1992/4885LMNA 935/4885ALDH1A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.